Business context and reporting period
The supplied filing is Helius Medical Technologies, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2023—not a filing for Solana Co. Helius develops and commercializes the PoNS neurostimulation device and therapy. U.S. commercial sales began in April 2022; the device has also been sold in Canada.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Total revenue | $111,000 | $190,000 |
| Gross profit (loss) | ($11,000) | $66,000 |
| Operating expenses | $3.799 million | $4.630 million |
| Operating loss | ($3.810 million) | ($4.564 million) |
| Net loss | ($2.494 million) | ($4.346 million) |
| Operating cash use | $3.190 million | $4.682 million |
- Product sales were $106,000, including $75,000 in the U.S. and $31,000 in Canada. Gross margin was approximately negative 10%, versus approximately 35% a year earlier.
- Cash and cash equivalents were $11.340 million at March 31, 2023, down from $14.549 million at year-end 2022. Working capital was $11.420 million. Total liabilities were $7.688 million, including a $5.696 million warrant derivative liability; the filing does not report conventional borrowings.
- Accumulated deficit was $153.601 million. The $1.221 million gain from the change in fair value of the warrant liability reduced reported net loss; it was noncash and reflected a decline in the company’s share price.
Material changes versus the prior comparable period
- Revenue fell 42%, chiefly because Canadian product sales declined by $152,000; U.S. sales contributed $75,000, as U.S. commercialization began after the prior-year quarter. The 2022 Canadian comparison included about $120,000 from delivery of 16 devices associated with the Heuro Canada acquisition.
- Research and development expense declined $878,000 as the company shifted focus from product development and clinical trials toward U.S. commercialization. Lower operating expenses and higher nonoperating income contributed to a narrower net loss.
- Operating cash use improved by $1.492 million year over year. Cash nevertheless declined by $3.209 million during Q1 2023.
Outlook, risks and unusual items
- Management said existing capital resources were expected to fund operations through 2023, but additional equity or debt financing would be needed thereafter. The company also expects to need funding for a planned stroke clinical trial. The filing states there is substantial doubt about the company’s ability to continue as a going concern within one year after filing; it warns that insufficient funding could force reduced operations or cessation.
- PoNS is not covered by CMS or broadly reimbursed by U.S. third-party payors. The company expected self-pay patients to remain the primary U.S. sales source before coverage, anticipated broad reimbursement could take at least 24 months, and expected to re-engage with CMS in mid-2023 after gathering further clinical and real-world evidence.
- Health Canada authorized PoNS for stroke-related gait deficit in March 2023. A new distribution agreement grants Health Tech Connex exclusive rights in specified British Columbia regions through December 2027, subject to terms.
- Nasdaq granted an extension through September 18, 2023 to regain compliance with its $1.00 minimum bid-price requirement. The company sought stockholder authority for a reverse split within a 1-for-10 to 1-for-80 range; failure to regain compliance could risk delisting and impair capital raising.
- The August 2022 offering included 36 million liability-classified public warrants, exercisable at $0.75 per share. The company granted 9.949 million stock options in Q1 2023. These securities may be important to assess for potential dilution; the public warrants were out of the money during the quarter.
- Other stated risks include uncertain capital-market access, inflation, interest rates, supply-chain and labor constraints, commercialization and reimbursement execution, and clinical and regulatory outcomes. Management reported no material legal proceedings and no material change in previously disclosed risk factors.
Important facts for investors to verify
- Confirm the issuer: this source is Helius Medical Technologies, Inc. (Nasdaq: HSDT), not Solana Co.
- Track cash burn, financing plans, and whether capital remains sufficient beyond 2023, given the explicit going-concern uncertainty.
- Monitor PoNS sales by geography, gross margins, customer concentration, and progress toward U.S. reimbursement and clinical evidence milestones.
- Check Nasdaq bid-price compliance and the outcome and implementation, if approved, of the proposed reverse split.
- Assess warrant and option terms, accounting valuation, and potential dilution. A single customer represented 14% of Q1 2023 product sales and 67% of accounts receivable at quarter-end.